Communicate, Educate, Inform


Cancer & COVID-19: Resources for Providers, Patients, and Caregivers

The following resources may be applicable to your work or individuals you serve, the page will be updated routinely as new information becomes available. 

Coronavirus Data & Information for Idaho

Covid-19 General Information

Cancer Screening & Treatment

Cancer Survivor Quality of Life & Mental Health

Services to support optimal physical, emotional, and social health among cancer patients, survivors, and caregivers help to improve quality of life and mental wellness.  Here are some resources to support these needs.

American Cancer Society 

If you’re having trouble finding the information you need about coronavirus and COVID-19, the illness caused by the current strain of coronavirus, we’re here to help with current and reliable information. 

We are available via live chat or our 24-hour helpline at 800-227-2345.

Cancer Care: COVID Resources 

Short Term Counseling/Hopeline and COVID 19 webcast

Hopeline Hours (800-813-HOPE)

Monday – Thursday: 10 a.m. – 6 p.m. EST

Friday: 10 a.m. – 5 p.m. EST

Covid-Stress and Coping

FDA and Coronavirus Disease 2019

World Health Organization - (COVID-19) advice for the public


Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Disaster Distress Helpline:

1-800-985-5990 or text TalkWithUs to 66746

American Psychological Association (APA)

APA COVID-19 Information and Resources

Continually updated by APA for psychologists, health-care workers and the public

National Alliance on Mental Illness (NAMI) Helpline

(particularly helpful for those with underlying MH diagnosis)

Monday-Friday, 10:00 a.m. to 6:00 p.m., EST

(800) 950-6264

ASCO Coronavirus Resources

As the nation continues to respond to the coronavirus (COVID-19) pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that individuals with cancer receive high-quality care.

Financial Resources for Cancer Patients

Financial and Social Support - Idaho 

COVID-19 and Cancer Research

Research - Publications 

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Lee et al, The Lancet 

  • Prospective observational study, eligible patients were those with active cancer who had a positive test result for SARS-CoV-2 on RT-PCR assay from a nose or throat swab. The primary endpoint was all-cause mortality or discharge from the hospital. Among 800 patients, 226(28%) died and risk of death was significantly associated with advancing age, being male, and presence of other comorbidities. After adjusting for those, chemotherapy in the past 4 weeks had no significant effect on mortality, nor did immunotherapy, hormonal therapy, targeted therapy, or radiotherapy within the past 4 weeks. 

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Kuderer et al, The Lancet
  1. Cohort study on adults with active or previous malignancy; primary endpoint all-cause mortality within 30 days of diagnosis. The authors found significant associations with increased 30-day all-cause mortality and the general factors of increasing age, male sex, former smoking, number of comorbidities, and receipt of azithromycin plus hydroxychloroquine; and the cancer-specific factors of moderate or poor Eastern Cooperative Oncology Group performance status and active (measurable) cancer. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality

  1. The authors argue for a careful balance weighing harms of postponing or cancelling treatment against the risks of infection and morbidity for patients, health care workers, and larger communities. The authors share a novel clinical process and flowchart for stakeholders to use in determining optimal treatment decisions for individual patients.

Last Updated 7/8/2020